EHA 2022 | Safety & efficacy cesnicabtagene autoleucel (ARI0002H) in R/R multiple myeloma

Despite significant improvements in the treatment of relapsed/refractory (R/R) multiple myeloma, patient survival remains poor. Over the past few years, CAR-T therapy has significantly improved patient outcomes. The most widely used and studied CAR target is the B-cell maturation antigen (BCMA) and two CAR-T therapies targeting BCMA have been approved to date. In this video, Carlos Fernandez de Larrea, University of Barcelona, Barcelona, Spain, reports the safety and efficacy results of the CARTBCMA-HCB-01 multicenter study evaluating cesnicabtagene autoleucel (ARI0002H), an academic BCMA-directed CAR-T product with a 4-1BB co-stimulatory domain, in patients with R/R multiple myeloma (NCT04309981). Dr Fernandez de Larrea explains that patients were treated locally with a fractionated initial dose followed by a booster dose. The study showed that all patients achieved a response, with 63% of patients achieving complete remission (CR). In addition, the measurable residual disease (MRD) negativity rates reached 92% after 100 days. Moving forward, Dr Fernandez de Larrea comments on the safety profile of ARI0002h and explains that there were no severe cases of cytokine release syndrome (CRS) and neurological events, suggesting this CAR-T product may be a promising option for patients with R/R multiple myeloma. This press briefing was recorded at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.